This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)
Clinical trial NCT04417036 · TERMINATED
Trial details
- NCT number
- NCT04417036
- Sponsor
- Bayer
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-07
- Primary completion
- 2022-12-28
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.